JP2004501608A - Ｖｅｇｆ調節遺伝子及びそれらを利用する方法 - Google Patents

Ｖｅｇｆ調節遺伝子及びそれらを利用する方法 Download PDF

Info

Publication number
JP2004501608A
JP2004501608A JP2001568372A JP2001568372A JP2004501608A JP 2004501608 A JP2004501608 A JP 2004501608A JP 2001568372 A JP2001568372 A JP 2001568372A JP 2001568372 A JP2001568372 A JP 2001568372A JP 2004501608 A JP2004501608 A JP 2004501608A
Authority
JP
Japan
Prior art keywords
vegf
polypeptide
activity
expression
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001568372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501608A5 (enExample
Inventor
ラステッリ，ルカ，ケー．
ガーバー，ハンス−ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2004501608A publication Critical patent/JP2004501608A/ja
Publication of JP2004501608A5 publication Critical patent/JP2004501608A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2001568372A 2000-03-21 2001-03-21 Ｖｅｇｆ調節遺伝子及びそれらを利用する方法 Pending JP2004501608A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19120100P 2000-03-21 2000-03-21
PCT/US2001/009043 WO2001070174A2 (en) 2000-03-21 2001-03-21 Vegf-modulated genes and methods employing them

Publications (2)

Publication Number Publication Date
JP2004501608A true JP2004501608A (ja) 2004-01-22
JP2004501608A5 JP2004501608A5 (enExample) 2008-05-08

Family

ID=22704517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001568372A Pending JP2004501608A (ja) 2000-03-21 2001-03-21 Ｖｅｇｆ調節遺伝子及びそれらを利用する方法

Country Status (6)

Country Link
US (3) US20020132978A1 (enExample)
EP (1) EP1290005A4 (enExample)
JP (1) JP2004501608A (enExample)
AU (2) AU2001250912B2 (enExample)
CA (1) CA2403804A1 (enExample)
WO (1) WO2001070174A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082412A1 (ja) * 2004-02-26 2005-09-09 Perseus Proteomics Inc. 癌の治療および予防薬
JPWO2005094888A1 (ja) * 2004-03-31 2008-02-14 株式会社ツーセル 損傷組織の治療剤と治療方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314424A1 (en) * 2000-08-16 2003-05-28 Chugai Seiyaku Kabushiki Kaisha Seamless soft capsule preparations containing dihydrobenzofuran derivatives
ES2353490T3 (es) * 2001-03-20 2011-03-02 Cns Protein Therapeutics, Inc. Factores de estimulación de la supervivencia neuronal dopaminérgica y sus utilizaciones.
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
WO2007068784A1 (en) 2005-12-14 2007-06-21 Licentia Ltd Novel neurotrophic factor protein and uses thereof
EP1644406B1 (en) 2003-07-11 2012-08-15 DeveloGen Aktiengesellschaft Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
EP1869076A2 (en) * 2005-03-10 2007-12-26 Genentech, Inc. Methods and compositions for modulating vascular integrity
EP2271358B1 (en) * 2008-03-25 2018-11-21 Amarantus Therapeutics, Inc. use of mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease
EP2280988B1 (en) * 2008-04-23 2017-05-24 Novacell Technology Inc. Angiogenic peptide
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
US9447152B2 (en) 2008-07-07 2016-09-20 Oxford Nanopore Technologies Limited Base-detecting pore
US20110229877A1 (en) 2008-07-07 2011-09-22 Oxford Nanopore Technologies Limited Enzyme-pore constructs
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
WO2010017224A2 (en) 2008-08-05 2010-02-11 University Of South Florida Methods of treating cognitive impairment
CN102113396B (zh) 2008-08-06 2013-10-16 夏普株式会社 通信系统、移动站装置以及通信方法
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
JP5843614B2 (ja) 2009-01-30 2016-01-13 オックスフォード ナノポア テクノロジーズ リミテッド 膜貫通配列決定における核酸構築物のためのアダプター
CA2750874A1 (en) * 2009-01-30 2010-08-05 Oxford Nanopore Technologies Limited Hybridization linkers
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
WO2012094600A1 (en) * 2011-01-06 2012-07-12 William Marsh Rice University Methods for treating lysosomal storage diseases using l-type ca2+ channel blockers with a 1,4 dihydropyridine structure and inhibitors of er-associated degradation
KR101939420B1 (ko) 2011-02-11 2019-01-16 옥스포드 나노포어 테크놀로지즈 리미티드 돌연변이체 세공
EA201400002A1 (ru) * 2011-06-09 2014-08-29 Юниверсити Оф Майами Способы лечения заболеваний сетчатки
JP6298404B2 (ja) 2011-07-25 2018-03-20 オックスフォード ナノポール テクノロジーズ リミテッド 膜貫通ポアを用いる二重鎖ポリヌクレオチド配列決定のためのヘアピンループ方法
CN112646019B (zh) 2012-04-10 2022-08-16 牛津纳米孔科技公开有限公司 突变胞溶素孔
EP2875154B1 (en) 2012-07-19 2017-08-23 Oxford Nanopore Technologies Limited SSB method for characterising a nucleic acid
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
AU2014224432B2 (en) 2013-03-08 2019-10-24 Oxford Nanopore Technologies Limited Enzyme stalling method
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
EP3137490B1 (en) 2014-05-02 2021-01-27 Oxford Nanopore Technologies Limited Mutant pores
US10400014B2 (en) 2014-09-01 2019-09-03 Oxford Nanopore Technologies Ltd. Mutant CsgG pores
US10266885B2 (en) 2014-10-07 2019-04-23 Oxford Nanopore Technologies Ltd. Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
CA3077518C (en) * 2016-09-07 2021-10-19 Frederic Fellouse Synthetic antibodies against vegf and their uses
JP2021519578A (ja) * 2018-03-29 2021-08-12 ヘルシンギン ユリオピストＨｅｌｓｉｎｇｉｎ Ｙｌｉｏｐｉｓｔｏ Ｃ末端ｃｄｎｆ断片、それらを含む医薬組成物、並びにそれらの使用
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
AU2019296451B2 (en) 2018-06-29 2021-04-29 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
SG11202101032VA (en) * 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Ltd Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT374041B (de) * 1982-03-25 1984-03-12 Naimer H L Stern-dreieck-schalter mit nullspannungsausloesung
US4758195A (en) * 1986-09-08 1988-07-19 3 W Designers, Inc. Elastomeric foam building units
FR2626254B1 (fr) * 1988-01-27 1990-07-06 Valois Sa Poussoir-etui avec systeme de garantie
US5174392A (en) * 1991-11-21 1992-12-29 Reinhardt Paul A Mechanically actuated fluid control device for downhole fluid motor
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE4340891A1 (de) * 1993-12-01 1995-06-08 Mahle Gmbh Hubkolben für Verbrennungsmotoren aus insbesondere Leichtmetall
US5856103A (en) * 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US6410046B1 (en) * 1996-11-19 2002-06-25 Intrabrain International Nv Administering pharmaceuticals to the mammalian central nervous system
MXPA02002765A (es) * 1999-09-16 2005-09-08 Prescient Neuropharma Inc Factores promotores de supervivencia neuronal, opaminergicos y sus usos.
WO2001025427A1 (fr) * 1999-10-01 2001-04-12 Kyowa Hakko Kogyo Co., Ltd. Adn reagissant a la contrainte de cisaillement
EP1869076A2 (en) * 2005-03-10 2007-12-26 Genentech, Inc. Methods and compositions for modulating vascular integrity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010075535, Ｂｒ． Ｊ． Ｐｈａｒｍａｃｏｌ．, 1999, ｖｏｌ．１２７， ｎｏ．２, ｐｐ．５３７−５４５ *
JPN6010075537, Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．, 1998, ｖｏｌ．２７３， ｎｏ．８, ｐｐ．４４００−４４０５ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082412A1 (ja) * 2004-02-26 2005-09-09 Perseus Proteomics Inc. 癌の治療および予防薬
JPWO2005094888A1 (ja) * 2004-03-31 2008-02-14 株式会社ツーセル 損傷組織の治療剤と治療方法
US8119397B2 (en) 2004-03-31 2012-02-21 Two Cells Co., Ltd. Therapeutic agents and therapeutic methods for treating injured tissue

Also Published As

Publication number Publication date
US20020132978A1 (en) 2002-09-19
WO2001070174A2 (en) 2001-09-27
US20080166724A1 (en) 2008-07-10
AU2001250912C1 (en) 2001-10-03
EP1290005A2 (en) 2003-03-12
AU5091201A (en) 2001-10-03
US20040006780A1 (en) 2004-01-08
EP1290005A4 (en) 2005-04-20
WO2001070174A8 (en) 2003-01-16
AU2001250912B2 (en) 2007-01-04
WO2001070174A3 (en) 2002-04-11
CA2403804A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
AU2001250912C1 (en) VEGF-modulated genes and methods employing them
AU2001250912A1 (en) VEGF-modulated genes and methods employing them
EP1265914B1 (en) Wnt-1 related polypeptides, and nucleic acids encoding the same
AU2001247781A1 (en) Novel polypeptides, and nucleic acids encoding the same
EP1265920B1 (en) Angiogenesis-associated proteins, and nucleic acids encoding the same
WO1999002724A2 (en) Methods for identifying genes expressed in selected lineages, and a novel genes identified using the methods
AU2001268715B2 (en) CGI-69 compositions and methods of use
JP2004519250A (ja) 新規ヒトｓｔｒａ６様タンパク質およびこれをコードする核酸
AU2001249450A1 (en) Angiogenesis associated proteins, and nucleic acids encoding the same
US20030104351A1 (en) FIZZ1 for metabolism regulation
US20060074023A1 (en) Angiogenesis associated proteins, and nucleic acids encoding the same
JP2004522405A (ja) Ｉｆｉ２０６、新規インターフェロン誘導ポリペプチド、及びこれをコードする核酸
AU2002254486A1 (en) FIZZ1 for metabolism regulation
AU2001297935A1 (en) Human Stra6-like protein and nucleic acids encoding the same
CA2447209A1 (en) Compositions and methods for adipose abundant protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111011